Compara mètodes

	Índex SCORAD (SCORing Atopic Dermatitis)	POEM (Patient-Oriented Eczema Measure)	Escala Visual Analògica del Picor (EVA Picor)
Camp	Dermatologia	Dermatologia	Dermatologia
Família	Process / pipeline	Process / pipeline	Process / pipeline
Any d'origen	1993	2004	1983 (VAS); widely adopted for pruritus 1990s–2000s
Autor original	European Task Force on Atopic Dermatitis (ETFAD)	Charman CR, Venn AJ, Williams HC	Huskisson EC (VAS methodology); adapted for pruritus in dermatology
Tipus	Clinician-rated	Self-report	Self-report
Font seminal	Kunz B, Oranje AP, Labrèze L, et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1997;195(1):10-19.	Charman CR, Venn AJ, Williams HC. The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol. 2004;140(12):1513-1519.	Elman S, Hynan LS, Gabriel V, Mayo MJ. The 5-D itch scale: a new measure of pruritus. Br J Dermatol. 2010;162(3):587-593.
Àlies	SCORAD Index	POEM Score	Itch VAS, Pruritus Severity Scale
Relacionats	3	2	3
Resum	The SCORAD is a comprehensive clinician-administered tool for measuring the extent and severity of atopic dermatitis (eczema). Developed by the European Task Force on Atopic Dermatitis in 1993, it combines objective clinical assessment with subjective symptom reporting. It is the gold standard for atopic dermatitis severity in clinical trials and dermatology practice.	The POEM is a brief, patient-administered severity measure for atopic dermatitis that focuses on frequency of symptoms experienced over the past week. Developed by Charman, Venn, and Williams in 2004, it emphasizes the patient's lived experience rather than clinician observation, making it practical for routine clinical practice and remote monitoring. POEM is increasingly used alongside objective measures in clinical trials and outpatient care.	The Pruritus Visual Analog Scale (VAS) is a simple, single-item patient-administered tool measuring itch intensity on a continuous 0–10 (or 0–100) scale. Adapted from the original VAS for pain, it is one of the most frequently used outcome measures in dermatological research and clinical practice due to its simplicity, brevity, and responsiveness to treatment. Pruritus VAS is essential in trials of antipruritic therapies and in conditions where itching is a primary complaint (atopic dermatitis, psoriasis, pruritus ani, lichen planus).